Reports have proliferated of late about how Ozempic and another new drug, Wegovy, will change how Americans eat and so help the health of many, many now-overweight people.

Moneyzine.com, for example, recently published Which Industries Could Benefit or Lose The Most Due To Ozempic?

Among its key findings:

• By 2035, an estimated 7% of the entire U.S. population could be on Ozempic.
• The demand for snack and convenience foods could potentially decrease by up to 3%.
• Ozempic usage may result in a $3.5 billion deficit for the alcohol industry.
• Gym memberships have doubled since the advent of Ozempic.
• United Airlines stands to save $80 million annually with the increased use of GLP-1 medications (Lighter-weight passengers mean less fuel consumption, one assumes).

All of that coming with the drugs available only to those in income brackets who can afford them at their current prices.

Continue reading “Will new weight-loss drugs change how you eat? Many think so but I have questions” →